SCHEMBL5863376

SCHEMBL5863376

Cc1c(C(=O)O)ccnc1N1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.48
POLB P06746 1/20 0.48
KIT P10721 2/20 0.47
CKS1B P61024 2/20 0.47
SKP1 P63208 2/20 0.47
SKP2 Q13309 2/20 0.47
GBA1 P04062 2/20 0.46
GPR119 Q8TDV5 5/20 0.46
MAPT P10636 2/20 0.44
ALDH1A1 P00352 1/20 0.44
LMNA P02545 1/20 0.44
PTPN11 Q06124 1/20 0.44
MEN1 O00255 1/20 0.44
TSHR P16473 1/20 0.44
KMT2A Q03164 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
GRIA1 P42261 1/20 0.44
PDE10A Q9Y233 1/20 0.43
MAP4K4 O95819 1/20 0.43
NR1H2 P55055 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5863371 0.86 MAPT (0.46) ACHEPOLBKITCKS1BSKP1
SCHEMBL4554527 0.84 POLB (0.61) ACHEPOLBKITCKS1BSKP1
SCHEMBL26107084 0.80 KIT (0.48) ACHEPOLBKITCKS1BSKP1
SCHEMBL23560764 0.79 GPR119 (0.50) ACHEPOLBKITCKS1BSKP1
SCHEMBL17145075 0.79 KMT2A (0.48) ALDH1A1LMNAMEN1TSHRKMT2A
SCHEMBL8701721 0.79 MAPT (0.53) POLBCKS1BSKP1SKP2GPR119
SCHEMBL3436722 0.79 POLB (0.57) ACHEPOLBKITCKS1BSKP1
SCHEMBL31652064 0.78 GPR119 (0.47) ACHEPOLBKITCKS1BSKP1
SCHEMBL17145030 0.77 KMT2A (0.47) MAPTALDH1A1LMNAMEN1TSHR
SCHEMBL23932490 0.77 KIT (0.54) POLBKITCKS1BSKP1SKP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7030120-B2 Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same MEIJI SEIKA KAISHA, LTD. (JP) 2006-04-18 US disclosed
US-20040224959-A1 Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same OHKURA NAOTO (JP) 2004-11-11 US disclosed
US-6777414-B1 INHIBITORS OF TRIGLYCERIDE BIOSYNTHESIS AND SECRETION OF APOLIPOPROTEIN B-CONTAINING LIPOPROTEINS; ARTERIOSCLEROTIC DISEASES; HYPERLIPIDEMIA MEIJI SEIKA KAISHA, LTD. (JP) 2004-08-17 US disclosed
EP-1180514-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND BENAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME MEIJI SEIKA KAISHA LTD. (JP) 2002-02-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224959-A1 Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same APOB, NCEH1, LIPC ACHE 2005/4885POLB 1984/4885KIT 3353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.